Medprin Regenerative Medical Technologies Co. Ltd. Asset Resilience Ratio
Medprin Regenerative Medical Technologies Co. Ltd. asset resilience ratio. Medprin Regenerative Medical Technologies Co. Ltd. (301033) has an Asset Resilience Ratio of 19.31% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Medprin Regenerative Medical Technologie to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Medprin Regenerative Medical Technologies Co. Ltd. (2019–2024)
Asset resilience ratio of Medprin Regenerative Medical Technologies Co. Ltd. from 2019 to 2024. This chart shows how Medprin Regenerative Medical Technologies Co. Ltd.'s Asset Resilience Ratio has changed over time. Read Medprin Regenerative Medical Technologie balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Medprin Regenerative Medical Technologies Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 301033 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥155.45 Million | 19.31% |
| Total Liquid Assets | CN¥155.45 Million | 19.31% |
Asset Resilience Insights
- Good Liquidity Position: Medprin Regenerative Medical Technologies Co. Ltd. maintains a healthy 19.31% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Medprin Regenerative Medical Technologies Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Medprin Regenerative Medical Technologies Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Medprin Regenerative Medical Technologies Co. Ltd. Asset Resilience Ratio by Year (2019–2024)
Medprin Regenerative Medical Technologies Co. Ltd. asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Medprin Regenerative Medical Technologies Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.25% | CN¥137.85 Million ≈ $20.17 Million |
CN¥799.23 Million ≈ $116.95 Million |
-7.25pp |
| 2023-12-31 | 24.50% | CN¥192.82 Million ≈ $28.22 Million |
CN¥786.97 Million ≈ $115.16 Million |
+4.76pp |
| 2022-12-31 | 19.74% | CN¥147.07 Million ≈ $21.52 Million |
CN¥744.92 Million ≈ $109.01 Million |
-30.55pp |
| 2021-12-31 | 50.29% | CN¥375.57 Million ≈ $54.96 Million |
CN¥746.78 Million ≈ $109.28 Million |
+6.51pp |
| 2020-12-31 | 43.78% | CN¥199.33 Million ≈ $29.17 Million |
CN¥455.34 Million ≈ $66.63 Million |
-1.15pp |
| 2019-12-31 | 44.93% | CN¥152.77 Million ≈ $22.36 Million |
CN¥340.05 Million ≈ $49.76 Million |
-- |
About Medprin Regenerative Medical Technologies Co. Ltd.
Medprin Regenerative Medical Technologies Co., Ltd. engages in the research, development, manufacture, and sale of implantable medical devices. The company offers artificial dura matermembrane patches, craniomaxillofacial repair and fixation systems, and absorbable regenerative oxidation for neurosurgery meningeal repair, skull repair fixation and rapid hemostasis, etc. It also offers ReDura, a S… Read more